Delayed Nyse  -  04:00 2022-06-27 pm EDT
182.12 USD   -0.09%
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia Drug
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Treat Chronic Lymphocytic Leukemia
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Janssen Oncology Strategy and Portfolio

05/25/2022 | 04:19pm EDT

NEW BRUNSWICK, NJ, May 25, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast is intended for investors and other interested parties, and will be available beginning at 8:00 a.m. ET on Tuesday, May 31, 2022.
The webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC, who will highlight key clinical data from across the portfolio and pipeline, including CARVYKTI™ (ciltacabtagene autoleucel), RYBREVANT® (amivantamab-vmjw), IMBRUVICA® (ibrutinib), BALVERSA® (erdafitinib) and teclistamab. Dr. Lebowitz will also discuss the company's oncology scientific and open innovation strategies in the key disease areas of focus (e.g., hematologic malignancies, prostate cancer, lung cancer, bladder cancer, etc.) and Johnson & Johnson's future in oncology.

The webcast can be accessed by visiting the Johnson & Johnson website at and clicking on "Webcasts/Presentations." The webcast duration is approximately 30 minutes and will be available through the end of July.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

  • Press Contacts:
    Brian Kenney
    (215) 620-0111

    Suzanne Frost
    (416) 317-0304

    Investor Contacts:
    Jessica Moore
    (732) 524-2955

    Raychel Kruper
    (732) 524-6164


Johnson & Johnson published this content on 25 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2022 20:18:27 UTC.

© Publicnow 2022
All news about JOHNSON & JOHNSON
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
06/24JOHNSON & JOHNSON'S JANSSEN : CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
06/23JOHNSON & JOHNSON : Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
06/22WALL STREET STOCK EXCHANGE : Powell's tall order to reassure investors
06/22Daiwa Securities Starts Johnson & Johnson at Outperform With $180 Price Target
06/22ANALYST RECOMMENDATIONS : Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone...
06/21TRANSCRIPT : Johnson & Johnson - Special Call
06/21Johnson & Johnson Opens Asia-Pacific Satellite Center for Global Health Discovery in Si..
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 499 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 21,2x
Yield 2022 2,45%
Capitalization 479 B 479 B -
EV / Sales 2022 4,87x
EV / Sales 2023 4,58x
Nbr of Employees 141 700
Free-Float 84,2%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 182,12 $
Average target price 188,12 $
Spread / Average Target 3,29%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON6.56%479 678
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202
NOVO NORDISK A/S6.98%253 053